Cantargia AB (STU:7V3) E10: €-0.16 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:7V3 Cantargia AB STU:7V3
44 GF Score
Price €0.15
! 2 Warning Signs
View Full Analysis

What is Cantargia AB E10?

Cantargia AB STU:7V3 -2.56% 44 E10 is €-0.16 as of Mar. 2026. GuruFocus rates STU:7V3 with a GF Score™ of 44/100. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Cantargia AB's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.012. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-0.16 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-13), Cantargia AB's current stock price is €0.152. Cantargia AB's E10 for the quarter that ended in Mar. 2026 was €-0.16. Cantargia AB's Shiller PE Ratio of today is .


Cantargia AB  (STU:7V3) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Cantargia AB E10 Related Terms


Cantargia AB E10 Historical Data

* Premium members only.

The historical data trend for Cantargia AB's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cantargia AB E10 Chart

Cantargia AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -0.18 -0.18 -0.17

Cantargia AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.20 -0.13 -0.17 -0.17 -0.16

STU:7V3 vs VRTX, REGN, ALNY: E10 Comparison

For the Biotechnology subindustry, Cantargia AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cantargia AB Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cantargia AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cantargia AB's Shiller PE Ratio falls into.


STU:7V3
44GF Score
Cantargia AB STU:7V3
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cantargia AB E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cantargia AB's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.012/133.5600*133.5600
=-0.012

Current CPI (Mar. 2026) = 133.5600.

Cantargia AB Quarterly Data

per share eps CPI Adj_EPS
201606 -0.039 101.019 -0.052
201609 -0.060 101.138 -0.079
201612 -0.098 102.022 -0.128
201703 -0.057 102.022 -0.075
201706 -0.043 102.752 -0.056
201709 -0.031 103.279 -0.040
201712 -0.032 103.793 -0.041
201803 -0.017 103.962 -0.022
201806 -0.035 104.875 -0.045
201809 -0.026 105.679 -0.033
201812 -0.033 105.912 -0.042
201903 -0.029 105.886 -0.037
201906 -0.027 106.742 -0.034
201909 -0.028 107.214 -0.035
201912 -0.040 107.766 -0.050
202003 -0.037 106.563 -0.046
202006 -0.033 107.498 -0.041
202009 -0.034 107.635 -0.042
202012 -0.050 108.296 -0.062
202103 -0.059 108.360 -0.073
202106 -0.059 108.928 -0.072
202109 -0.085 110.338 -0.103
202112 -0.144 112.486 -0.171
202203 -0.111 114.825 -0.129
202206 -0.088 118.384 -0.099
202209 -0.045 122.296 -0.049
202212 -0.042 126.365 -0.044
202303 -0.040 127.042 -0.042
202306 -0.029 129.407 -0.030
202309 -0.039 130.224 -0.040
202312 -0.036 131.912 -0.036
202403 -0.018 132.205 -0.018
202406 -0.021 132.716 -0.021
202409 -0.020 132.304 -0.020
202412 -0.018 132.987 -0.018
202503 -0.017 132.825 -0.017
202506 -0.015 133.699 -0.015
202509 0.097 133.480 0.097
202512 -0.012 133.390 -0.012
202603 -0.012 133.560 -0.012

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-0.16 mean?
Cantargia AB (STU:7V3) has a E10 of €-0.16 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Cantargia AB and its competitors.
Is Cantargia AB's E10 too high?
Cantargia AB's current E10 is €-0.16. Overall, Cantargia AB has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Cantargia AB's E10 compare to VRTX and REGN?
Cantargia AB's E10 of €-0.16 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Cantargia AB and its competitors. Cantargia AB's current E10 is €-0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantargia AB stock overvalued right now?
Cantargia AB (STU:7V3) has a current E10 of €-0.16. The current E10 is €-0.16. Cantargia AB's overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Cantargia AB (STU:7V3), the current E10 is €-0.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cantargia AB Business Description

Other Exchanges CANTA:Sweden
Address Scheelevagen 27, Lund, SWE, 223 63
Cantargia AB is a Swedish biotech company that develops targeted antibody-based drugs for cancer as well as autoimmune and inflammatory diseases. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's development programme includes the candidate drugs nadunolimab (CAN04) and CAN10, both in the clinical development stage, which were latter acquired by Otsuka Pharmaceutical in 2025. In addition, the company is also developing a a pre-clinical project CAN14, derived from antibody platform CANxx. Geographically, the company's revenues have been generated in the markets of Japan and United States.
44GF Score

Get the complete analysis for STU:7V3

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.15
Price